Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer

Trial Profile

A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gancotamab (Primary) ; Trastuzumab (Primary) ; Capecitabine; Gemcitabine; Vinorelbine
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms HERMIONE
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 05 Jan 2017 This trial was suspended in Austria, according to European Clinical Trials Database.
    • 21 Dec 2016 Status changed from recruiting to discontinued, according to a Merrimack Pharmaceuticals media release. The decision was based on an independent Data and Safety Monitoring Board (DSMB) recommendation and subsequent futility analysis which determined that continuing would be unlikely to demonstrate benefit over the comparator treatments. Patients currently enrolled in the trial may choose to continue on their assigned treatment based upon discussion with their study physician.
    • 11 Oct 2016 As per the trial design presented at 41st European Society for Medical Oncology Congress, enrollment is expected to be complete in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top